Supplementary Table 1.

Primers	used	for	real	time	qPCF	2
---------	------	-----	------	------	------	---

Gene	Accession number	Forward/reverse primers
Tafa	NM_031199	5'-CCATCAGTCTACCCTTTGC
rgiù		5'-GGAGAAGGTACACAGCG
Tafß1	NM 011577	5'-GGCTACCATGCCAACTT
rgipi	NM_011577	5'-ACCCACGTAGTAGACGA
Haf	NM_010427	5'-AAATGAGAATGGTTCTTGGTG
, igi		5'-CTGGCCTCTTCTATGGCT
Cyclin A2	NM_009828	5'-GGCTGACACTCTTTCCG
0,000,000		5'-CTGGTAGCAAGAATTAGAGCAT
Cvclin B1	NM 172301	5'-AGCAAATATGAGGAGATGTACC
		5'-CGACTTTAGATGCTCTACGGA
Cvclin D1	NM 007631	5'-TCCCAGACGTTCAGAACC
		5'-AGGGCATCTGTAAATACACT
Cvclin E1	NM_007633	5'-TGCACCAGTTTGCTTATGTT
• • • • • • • • • • • • • • • • • • •		5'-CCGTGTCGTTGACATAGG
FoxM1	NM_008021	5'-CTTACTGCCCTTTCCTCG
		5'-GAACACTATCAGAGAAACACCTAAT
p21	NM_007669	5'-GGTTCCTTGCCACTTCTT
,		5'-GAGTCGGGATATTACGGTTG
Lrat	NM_023624	5'-AGTTCAAGACTAGCCTGCTCA
		5'-TACAAGCTGGCCTTCGAC
Cyp26A1	NM_007811	5'-AGAGCAATCAAGACAACAAGTTAG
		5'-ATCGCAGGGTCTCCTTAAT
Crbpl	NM_011254	5'-AATGAGAGCTGAGGGTG
		5'-GGTATGCGTTTCGGTCC
Rarβ	NM_011243	5'-CAAGTTCAAGTGGGAATATAGCAGA
		5'-ACTGACTGACTCCACTGTT
Bcmo1	NM_021486	5'-ATGAAATGTGGAGAAGACTTCTAT
		5'-CTTTGTCCACGACGGAT
Bcmo2	NM_133217	5'-AGGACCAGGGCTGTATTGTG
		5'-CGCTGGCTGAAGAATAGGAC

Pparα	NM_011144	5'-ACTGGATGACAGTGACATTTC
		5'-CTCCTGCAACTTCTCAATGTAG
Pparβ/δ	NM_011145	5'-GGGTCAGAAGCTAGACAGCGAG
		5'-AGAAAGAACAGCTATGGTCCAGTTCC
Ppary	NM_011146	5'-TCTCCAGCATTTCTGCTCCACAC
		5'-CAGGTTCTACTTTGATCGCACTTTGGTAT
Cb1	NM_007726	5'-CGTGTTCCACCGCAAAGATAGTC
		5'-GTACCTGTCGATGGCCGT
Cb2	NM_009924	5'-TGTGGGTCCTCTCAGCATTGATT
		5'-CCAGCCCAGTAGGTAGTCGTT
Pdk4	NM_013743	5'-TCGAACTCTTCAAGAATGCC
		5'-GGTCAGTAATCCTCAGAGGAACA
αSma	NM_007392	5'-TCTGGCACCACTCTTTCTATAAC
		5'-TAGCCACATACATGGCGG
Col1A1	NM_007742	5'-CCTCAGAAGAACTGGTACATCA
		5'-GGCCTCGGTGGACATTA
18S		5'-CCATCCAATCGGTAGTAGCG
		5'-GTAACCCGTTGAACCCCATT



Supplementary Figure 1. Serum alanine aminotransferase (ALT) activity for wild type and Lrat^{-/-} mice following sham operation. Values are given as the mean \pm 1 S.D., n = 10 for each time and genotype.



Supplementary Figure 2. Hgf, Tgf α and Tgf β mRNA expression in the livers of wild type and Lrat^{-/-} mice following PHE. Values are given as the mean ± 1 S.D., n = 10 for each genotype. Values marked with different letters (a, b, c) are significantly different, *P* < 0.05.



Supplementary Figure 3. II-6 and Tnf α mRNA expression in the livers of wild type and Lrat^{-/-} mice 12 h following PHE. Values are given as the mean ± 1 S.D., n = 10 for each genotype.



Supplementary Figure 4. Hepatic retinol levels in wild type and $Lrat^{-}$ mice following PHE and sham operation. Values are given as the mean ± 1 S.D., n = 10 for each time and genotype.



Β.



Supplementary Figure 5. Hepatic triglyceride accumulation in livers of wild type and $Lrat^{--}$ mice following PHE. Panel A. Representative H&E stained liver sections from wild type and $Lrat^{--}$ mice, 0, 12, and 72 h after PHE. Panel B. Representative oil red O stained liver sections from wild type and $Lrat^{--}$ mice, 0, 12, and 72 h after PHE.

Α.



Supplementary Figure 6. Hepatic triglyceride concentrations for wild type and $Lrat^{-}$ mice following sham operation. Values are given as the mean ± 1 S.D., n = 10 for each time and genotype.



Supplementary Figure 7. Summary of the effects identified in Lrat^{/-} mice which give rise

to impaired liver regeneration.



Supplementary Figure 8. Blood glucose levels in wild type and $Lrat^{-}$ mice following PHE and sham operation. Values are given as the mean ± 1 S.D., n = 10 for each time and genotype.